GUTTMAN-YASSKY, E.; BLAUVELT, A.; EICHENFIELD, L.; PALLER, A.; ARMSTRONG, A.; DREW, J.; GOPALAN, R.; SIMPSON, E. Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S41, 2019. DOI: 10.25251/skin.3.supp.41. Disponível em: https://dermsquared.com/skin/article/view/768. Acesso em: 20 sep. 2024.